Literature DB >> 12573136

PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells.

William A Wilmer1, Cynthia L Dixon, Courtney Hebert, Ling Lu, Brad H Rovin.   

Abstract

Transforming growth factor-beta1 (TGF-beta1) mediates the development of glomerulosclerosis by stimulating mesangial cell production of extracellular matrix (ECM) proteins. TGF-beta1 and several ECM genes are regulated by promoter O-tetradecanoylphorbol 13-acetate-responsive elements (TREs) that are transactivated by the activator protein-1 (AP-1) transcription factor complex. AP-1-TRE interactions are regulated by redox changes. Recently, peroxisome proliferator-activated receptors (PPARs) were shown to negatively regulate several transcription factor families. In these studies, we postulated that PPAR-alpha could antagonize TGF-beta1 expression by cultured human mesangial cells (HMC). A TGF-beta1 luciferase expression plasmid was transduced into HMC via recombinant deficient adenoviral vectors. The TGF-beta1 promoter activity increased twofold (209%) following 18-h treatments with H(2)O(2) (1,000 micro M). Using RT-PCR, we demonstrated that HMC possess PPAR-alpha RNA, and PPAR-alpha protein was identified by immunohistochemistry. Pretreatment of cells with the PPAR-alpha ligands WY14643 (100-500 micro M) or clofibrate (100-500 micro M) dose-dependently inhibited oxidant-mediated induction of TGF-beta1. This inhibition occurred without affecting the H(2)O(2)-mediated activation of the mitogen-activated protein kinase (MAPK) pathways extracellular regulated kinase, p38 MAPK, or Jun N-terminal kinase, which are responsible for the regulation of AP-1 phosphorylation. These studies are the first to identify PPAR-alpha expression by HMC. The results of these studies suggest that TGF-beta1 expression mediated by oxidant stress may be suppressible by PPAR-alpha activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12573136     DOI: 10.1089/152308602762197416

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  7 in total

1.  Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy.

Authors:  Lingyun Li; Nerimiah Emmett; David Mann; Xueying Zhao
Journal:  Exp Biol Med (Maywood)       Date:  2010-03

Review 2.  Novel Function for Bilirubin as a Metabolic Signaling Molecule: Implications for Kidney Diseases.

Authors:  David E Stec; Claudio Tiribelli; Olufunto O Badmus; Terry D Hinds
Journal:  Kidney360       Date:  2022-03-25

3.  Role of PPARα and Its Agonist in Renal Diseases.

Authors:  Ching-Feng Cheng; Hsi-Hsien Chen; Heng Lin
Journal:  PPAR Res       Date:  2010-11-08       Impact factor: 4.964

4.  Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy.

Authors:  Sungjin Chung; Cheol Whee Park
Journal:  Diabetes Metab J       Date:  2011-08-31       Impact factor: 5.376

5.  The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.

Authors:  M C Thomas; K A Jandeleit-Dahm; C Tikellis
Journal:  PPAR Res       Date:  2012-02-12       Impact factor: 4.964

Review 6.  The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases.

Authors:  Jianjun Gao; Zhaoyan Gu
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

7.  Peroxisome proliferator-activated receptors in diabetic nephropathy.

Authors:  Shinji Kume; Takashi Uzu; Keiji Isshiki; Daisuke Koya
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.